Drug intelligence / Profile preview

CKD-4101

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CKD-4101 is a tablet formulation of mycophenolate mofetil developed by Chong Kun Dang Pharmaceutical. Mycophenolate mofetil is an immunosuppressive agent that acts as a prodrug of mycophenolic acid, which inhibits inosine monophosphate dehydrogenase, thereby suppressing the proliferation of T and B lymphocytes. CKD-4101 was evaluated in a Phase 1 clinical trial to compare its pharmacokinetic characteristics and safety profile with those of standard mycophenolate mofetil capsules in healthy volunteers[1][3][6]. The development status for this specific formulation appears to be pending or not actively pursued beyond early-phase studies[1][9].

Brand names: MyreptCellCept
Other names: CKD-4101CKD4101CKD 4101

Targets

IMPDH (Inosine-5'-monophosphate dehydrogenase 1)

Beyond the preview

Go deeper on CKD-4101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-4101.

Explore the full profile